View All Cancer Clinical Trials | The University of Kansas Cancer Center

Viewed View Trial

A Phase II study of TAS-102 in metastatic Platinum and checkpoint inhibitor?resistant bladder cancer

Study Type: Treatment

Phase: II

NCTID: NCT03762161

Principal Investigator: Rahul Parikh

Viewed View Trial

A Randomized Open-Label Phase II/III Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer Duravelo-2

Study Type: Treatment

Phase: II/III

NCTID: NCT06225596

Principal Investigator: Rahul Parikh

Viewed View Trial

A Pilot Study of Tazemetostat and Pembrolizumab MK-3475 in Advanced Urothelial Carcinoma

Study Type: Treatment

Phase: Feasibility/Pilot

NCTID: NCT03854474

Principal Investigator: Elizabeth Wulff-Burchfield

Viewed View Trial

A Randomized Phase II Study of Erdafitinib Versus Investigator Choice of Intravesicular Chemotherapy in Subjects Who Received Bacillus Calmette-Gu�rin BCG and Progressed or Recurred With High Risk Non-Muscle-Invasive Bladder Cancer NMIBC and FGFR Mutations or Fusions

Study Type: Treatment

Phase: II

NCTID: NCT04172675

Principal Investigator: Eugene Lee

Viewed View Trial

Implementation of Nutrition Education Videos for Patients Undergoing Radical Cystectomy

Study Type: Supportive Care

Phase: N/A

NCTID: NCT03801954

Principal Investigator: Eugene Lee

Viewed View Trial

Psychometric evaluation of a Patient-Reported Symptom Index for Non-Muscle Invasive Bladder Cancer: Field Testing

Study Type: Other

Phase: N/A

NCTID: NCT03091764

Principal Investigator: Eugene Lee

Viewed View Trial

IV Vitamin C with Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients: A Forgotten Group

Study Type: Treatment

Phase: I/II

NCTID: NCT04046094

Principal Investigator: John Taylor

Viewed View Trial

A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response DDR gene alterations

Study Type: Treatment

Phase: II

NCTID: NCT03609216

Principal Investigator: Eugene Lee

Viewed View Trial

A Phase III, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer IR-NMIBC Following Transurethral Resection of Bladder Tumor TURBT

Study Type: Treatment

Phase: III

NCTID: NCT06111235

Principal Investigator: Danica May

Viewed View Trial

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG?Na�ve High?Grade Non?Muscle Invasive Bladder Cancer.

Study Type: Treatment

Phase: III

NCTID: NCT03091660

Principal Investigator:

Find a Clinical Trial

A Phase II study of TAS-102 in metastatic Platinum and checkpoint inhibitor?resistant bladder cancer

A Randomized Open-Label Phase II/III Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer Duravelo-2

A Pilot Study of Tazemetostat and Pembrolizumab MK-3475 in Advanced Urothelial Carcinoma

A Randomized Phase II Study of Erdafitinib Versus Investigator Choice of Intravesicular Chemotherapy in Subjects Who Received Bacillus Calmette-Gu�rin BCG and Progressed or Recurred With High Risk Non-Muscle-Invasive Bladder Cancer NMIBC and FGFR Mutations or Fusions

Implementation of Nutrition Education Videos for Patients Undergoing Radical Cystectomy

Psychometric evaluation of a Patient-Reported Symptom Index for Non-Muscle Invasive Bladder Cancer: Field Testing

IV Vitamin C with Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients: A Forgotten Group

A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response DDR gene alterations

A Phase III, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer IR-NMIBC Following Transurethral Resection of Bladder Tumor TURBT

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG?Na�ve High?Grade Non?Muscle Invasive Bladder Cancer.

Popular Links